Disease Prevention

Disease prevention in Iran involves several tasks that require different evidence. Vaccination programmes seek to protect people before infection; surveillance identifies disease transmission and helps direct a response; prevention of noncommunicable diseases addresses risks that accumulate through everyday life. Noncommunicable diseases include cardiovascular disease, cancer, chronic respiratory disease and diabetes. WHO identifies tobacco, unhealthy diets, physical inactivity, harmful alcohol use and air pollution as major prevention priorities across the Eastern Mediterranean region, which includes Iran. These regional priorities provide context rather than a measurement of Iran’s individual performance. s4

For international readers, an important distinction is between a programme’s existence and its reach. A vaccine can enter the national schedule without every eligible child receiving it promptly. Likewise, a period without locally acquired infection does not remove the need for surveillance. Iran’s recent experience illustrates both distinctions. s1s2s3

UNICEF identifies vaccine access, storage and transport as practical concerns in Iran. The cold chain is the temperature-controlled system that keeps vaccines usable between procurement and administration. UNICEF’s programme description includes upgrading this system and addressing barriers to vaccination in disadvantaged communities. It also highlights the importance of reaching migrant and refugee children, because protection depends on coverage within communities rather than nationality. s1

There is documented evidence of expansion. An August 2025 UNICEF report states that pneumococcal conjugate vaccine entered Iran’s national immunization schedule in 2024. This vaccine targets infections caused by the bacterium Streptococcus pneumoniae, including some forms of pneumonia, meningitis and bloodstream infection. The report also records subsequent vaccine deliveries, including rotavirus vaccine. Procurement is evidence of supplies reaching the country; it does not independently establish uptake, timely completion or reductions in illness. s2

WHO’s World Malaria Report 2024 records a resurgence of locally acquired malaria in Iran beginning in 2022, following four consecutive years without indigenous cases. Its accompanying figure explicitly warns that the Iranian figures include both indigenous and introduced cases. These categories should therefore not be silently relabelled as a uniform series of indigenous infections. s3

WHO uses this experience to emphasize sustained investment, rapid detection and response, community participation and cooperation across borders. The lesson is operational: maintaining low transmission requires functioning surveillance even after disease becomes uncommon. This historical account does not establish Iran’s malaria situation in 2026. s3

The historical dataset below records WHO and UNICEF estimates of BCG coverage, meaning receipt of one dose of Bacillus Calmette–Guérin vaccine among births. It measures a specific vaccination indicator, not protection against all infectious diseases. The estimates combine assessment of reported information and other evidence; they are not annual household survey results. Their national scope also cannot establish equal coverage in every locality or population group. s5

Iran, national · gregorian